Imaging Cancer Using FAPI-PET to Detect Cancer-associated Fibroblasts
Tests a PET scan with FAPI-74 in people diagnosed with cancer, compared with FDG-PET.
Plain-language title generated from the registry record
Registry title: Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
Key facts
- Where
- Suita, JapanSee the site
Where in Japan
- Osaka University HospitalSuita, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tadashi Watabe
- Trial code
- NCT05442151
- Record updated
- 31 July 2025
- Original description
PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.Read full original descriptionShow less
Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
Inclusion: Patients who meet any of the following conditions; Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination; Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy; Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor.
Exclusion: Pregnant women or patients who may be pregnant; Pediatric patients requiring sedation; Those who are judged to be inappropriate as subjects.